Methods Patients
We examined patients aged ≥18 years who were admitted with HF in the first and second phases of the Enhanced Feedback For Effective Cardiac Treatment (EFFECT-HF) cohort, which has been described in detail elsewhere. 12, 13 Briefly, this was a 2-phase population-based retrospective chart review of a sample of patients presenting to acute care hospitals in Ontario, Canada, between 1999 and 2001 (phase I) and between 2004 and 2005 (phase II). To qualify for inclusion in this study, patients were required to meet the modified Framingham HF criteria at presentation and have a primary diagnosis of HF in the discharge abstract. 14 Clinical data, including admission vital signs, baseline investigations obtained in the emergency department, medications, and comorbidities, were abstracted from hospital records. Chart abstraction was performed by highly experienced cardiology nurses, with high data reliability. 13 To be included, patients were required to be in normal sinus rhythm throughout the duration of the hospital stay. Patients who were diagnosed with HF after admission, transferred from another acute care facility, pregnant, nonresidents, and those with invalid health card numbers were excluded. Patients with resting heart rate <40 bpm, diastolic blood pressure <80 or >115 on discharge, or a pacemaker in situ were excluded, as were those who developed a myocardial infarction, atrial fibrillation or flutter, heart block, sick sinus syndrome, and those who underwent coronary revascularization during the hospital stay. Institutional review board approval was obtained from all participating institutions before data linkage.
Definitions
Admission vital signs, laboratory values, and comorbidities were defined as the first values obtained within 24 hours of hospital presentation. Discharge heart rate was defined as the last recorded heart rate obtained within 24 hours before or at discharge from the hospital. Discharge heart rate was categorized into predefined groups: 40 to 60, 61 to 70, 71 to 80, 81 to 90, and >90 bpm. LVEF was determined by echocardiogram, radionuclide angiogram, or cardiac catheterization performed during hospitalization. Patients were classified as newly hospitalized if they had not been hospitalized for HF (International Classification of Diseases [ICD] Code 428.x, 9th revision, or I50.x, 10th revision) within 3 years before the index EFFECT hospital admission, determined by linking the clinical chart data with the Canadian Institute for Health Information Discharge Abstract Database.
Outcomes
The primary outcomes were all-cause mortality at 30 days and 1 year. In addition, we examined the effect of heart rate on cardiovascular death and hospital readmission for HF, ischemic heart disease, and cardiovascular disease. Mortality data were obtained through linkages to the Registered Persons Database and the Canadian Institute for Health Information database using the patients' encrypted health card number. Causes of death were identified from the Ontario Registrar General's vital statistics database. Readmissions for HF (ICD-9 code 428.x, ICD-10 code I50.x), ischemic heart disease (ICD-9 codes 410-414, ICD-10 codes I20-I25), and cardiovascular disease (ICD-9 codes 410- 414, 428, 390-398, 401-405, 415-417, 420-438, 440-448, 451-453, 458, 780.2, 785.5 , and 798.1 and ICD-10 codes I20-I25, I50, I00-I02, I05-I09, I34-I37, I10-I15, I25-I28, I30-I33, I38-I41,  I42, I43, I44-I49, I51, I52, I60-I74, I77-I82, I95 , R55, R57, and R96) were identified using the Canadian Institute for Health Information Discharge Abstract Database-linked administrative database.
Statistical Analysis
Continuous variables were reported as median (25th and 75th percentiles) and compared using the Kruskal-Wallis test. Categorical variables were reported as proportions and compared using the χ 2 test for trend. We performed multiple logistic regression analyses for mortality, adjusting the odds ratios (ORs) for all EFFECT risk score components that were entered separately into the model 13 and other covariates, including sex, admission heart rate, LVEF, New York Heart Association (NYHA) class, prior myocardial infarction (MI), pathogenic cause of HF, and discharge medications (β-adrenoreceptor antagonists, calcium channel blockers (CCBs), angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), digoxin, vasodilators, thyroid replacement, bronchodilators, and loop diuretics). Restricted cubic splines were used to model a nonlinear relationship between discharge heart rate and the adjusted log odds of mortality. Readmissions were analyzed using Cox proportional hazards regression analysis, adjusting for all covariates described above. The proportional hazards assumption was tested by using a Kolmogorov-type supremum test on 1000 resamplings of the cumulative sums of martingale residuals. 15 There was no evidence of violation of the proportional hazards assumption. Analyses were stratified by prior hospitalized versus newly hospitalized HF, discharge β-adrenoreceptor antagonist use, ischemic versus nonischemic cause, and reduced (≤45%) versus preserved (>45%) LVEF systolic function. Missing LVEF category (ie, reduced versus preserved) was imputed using a previously published method. 16 Statistical significance was defined by a 2-sided P<0.05. All analyses were performed using SAS version 9.3 for Unix (Cary, NC).
Results

Patient Characteristics by Discharge Heart Rate Category
A total of 9097 patients were included in the present study of which 4286 (47.1%) were men. Baseline characteristics are shown in Table 1 . Respiratory rate was slightly higher, and systolic blood pressure was lower in higher heart rate categories. Ischemic HF was progressively less common among those in higher heart rate categories, whereas chronic obstructive pulmonary disease was increasingly prevalent. Fewer patients in higher heart rate categories were prescribed β-adrenoreceptor antagonists at discharge, whereas more were prescribed bronchodilators.
Association of Discharge Heart Rate With All-Cause Mortality
There was a nonsignificant trend toward a greater risk of 30-day mortality at heart rates <60 bpm, which was not observed at 1 year. For this reason, in logistic regression analysis, the referent group for the analysis of 30-day mortality was the second category (heart rate, 61-70 bpm). For the analysis of 1-year mortality, the referent heart rate group was category 1 (40-60 bpm). Both crude and adjusted 30-day ORs for all-cause mortality were significantly greater among those in the 2 highest heart rate categories. Multivariable-adjusted ORs for 30-day mortality were 1.59 (95% confidence interval [CI], 1.18-2.14) for discharge heart rates 81 to 90 and 1.56 (95% CI, 1.13-2.16) for heart rates >90 bpm. One-year all-cause mortality was significantly greater in the highest heart rate category with an adjusted OR of 1.41 (95% CI, 1.16-1.72) for heart rates >90 bpm ( Table 2 ). In contrast to measurements at discharge, admission heart rate was not significantly associated with 30-day (adjusted OR, 1.02 per 10 bpm; 95% CI, 0.97-1.06; P=0.498) or 1-year (adjusted OR, 1.00 per 10 bpm; 95% CI, 0.98-1.03; P=0.765) mortality in the multivariable model that included admission and discharge heart rates and adjusted for all other covariates.
Stratification by Prior HF Status
Of the study cohort, 2714 (29.8%) had been previously hospitalized for HF. In stratified analyses, the OR of 30-day all-cause mortality was significantly higher among those who were newly admitted with a nonsignificant trend toward higher mortality among those who had been previously hospitalized (Table 3 ). However, 1-year-adjusted mortality was greater among those with higher heart rates, irrespective of prior HF hospitalization status. When compared with the multivariableadjusted model as shown in Table 2 
Association of Discharge Heart Rate in Stratified Analyses
Among patients with either ischemic or nonischemic HF, there was a linear trend toward higher log odds of 1-year allcause mortality with elevated heart rates (Figures 1 and 2) . A total of 5563 patients (61.2%) were pathogenically ischemic HF, and among these patients, there was a significantly greater odds of 1-year all-cause mortality in the highest heart rate category when compared with the referent group (Table 4) , with an adjusted OR of 1.36 (95% CI, 1.06-1.74). Among patients who were pathogenically non-ischemic, the odds of 1-year mortality in the highest heart rate group was also greater with an adjusted OR of 1.40 (95% CI, 1.02-1.92).
In our cohort, 1380 patients (32.8%) of those discharged on a β-adrenoreceptor antagonist were of ischemic cause, whereas 2828 (67.2%) were nonischemic. Among those not on a β-adrenoreceptor antagonist at admission or discharge, 1988 patients (44.9%) were classified as ischemic and 2439 (55.1%) were classified as nonischemic. The odds of all-cause mortality at 1-year was significantly higher among patients with heart rates >90 bpm who were prescribed a β-adrenoreceptor antagonist at discharge (adjusted OR, 1.56; 95% CI, 1.17-2.09). Among those not prescribed a β-adrenoreceptor antagonist on admission or discharge, there was a nonsignificant trend toward higher mortality with increasing heart rate when compared with the referent population (Table 4) .
Ejection fraction data were available for 3798 (41.8%) patients. Among those with preserved LVEF (>45%), the odds of all-cause mortality was significantly increased in the highest heart rate category (>90 bpm) with an adjusted OR of 1.49 (95% CI, 1.17-1.90). Among patients with a reduced LVEF (≤45%), there was a nonsignificant trend toward greater odds of death in the highest heart rate category ( Table 4 ).
Association of Discharge Heart Rate With Readmissions to Hospital
Readmissions for HF occurred among 1068 (11.7%) patients within 30 days after the index EFFECT hospital discharge. Repeat hospitalizations for ischemic heart disease occurred in 529 (5.8%) patients within 30 days and 2098 (23.1%) patients within 1 year. Readmissions for any cardiovascular disease occurred in 1414 (15.5%) patients within 30 days and 4613 (51.0%) patients within 1 year. The highest discharge heart rate category was associated with a greater risk of HF readmission and rehospitalization for any cardiovascular disease within 30 days postindex EFFECT discharge ( Table 5 ).
Cardiovascular Death and Discharge Heart Rate
The effect of discharge heart rate on cardiovascular death at 30-day and 1-year follow-up after index hospital discharge is shown in Figures 3 and 4 
Discussion
In this study, we found a positive association between increasing heart rate at discharge and all-cause mortality among community-based patients who were hospitalized with HF.
Attesting to the importance of this prognostic marker, the risk of cardiovascular death was also significantly associated with discharge heart rate after HF hospitalization. Moreover, this trend was seen among all subgroups examined and reached significance at heart rates >90 bpm among patients with ischemic and nonischemic HF, those discharged on a β-adrenoreceptor antagonist, and those with preserved LVEF. The nonsignificant increase in 30-day mortality in the lowest heart rate category (40-60 bpm) suggests that a discharge heart rate <60 bpm may be a marker of poor short-term prognosis. However, these effects were not observed at 1 year, suggesting that lower heart rates may provide potential longer term benefits. Interestingly, the effect of discharge heart rate was most pronounced among those who were newly hospitalized with HF with higher mortality at both 30 days and 1 year. Among those with prior HF hospitalizations, there was a greater OR of mortality with higher heart rate at 1 year, but this was not significant at 30 days. In addition to its effects on mortality, discharge heart rates >90 bpm were also associated with higher risk of subsequent HF readmission and cardiovascular disease hospitalization.
Our data are consistent with the growing body of literature, suggesting that elevated heart rate is associated with worse prognosis among patients with coronary artery disease, reduced LV function, and chronic HF. [8] [9] [10] [11] 17 In a post hoc analysis of the Treating to New Targets (TNT) trial, Ho et al 10 found that among patients with stable coronary artery disease, a heart rate ≥70 bpm was associated with higher allcause mortality and HF hospitalization. In a post hoc analysis of COMET (Carvedilol or Metoprolol European Trial), heart rates ≤68 bpm after 4 months on a β-adrenoreceptor antagonist were associated with significantly reduced mortality when compared with heart rates >68 bpm. 18 Moreover, in the DIAMOND (Danish Investigations of Arrhythmia and Mortality on Dofetilide) study, among patients with LV dysfunction with a previous hospitalization for HF or MI, there was increased mortality risk for each 10 bpm increase in baseline heart rate. 19 Consistent with our findings, these results were robust even when β-adrenoreceptor antagonists were included in the model. Our results extend the growing body of literature on heart rate in cardiovascular disease to the community-based HF population among ischemic and nonischemic subgroups.
Although our study is generally consistent with prior published studies on the effect of heart rate and HF prognosis, we observed differences in the threshold where significant increases in risk were observed. Specifically, in our community-based population, heart rates >90 bpm were associated with a wide range of adverse outcomes, whereas a lower threshold was used to define the higher risk subcohort in clinical trial settings. Interestingly, in the EFFECT-HF mortality risk model, heart rate at admission was not a predictor of 30-day or 1-year death among patients who were admitted to hospital. 13 This suggests the importance of timing because the present analysis found that heart rate measurement at discharge was a potent predictor of outcome among those who survived their hospital stay in the transition to the ambulatory care setting.
Elevated heart rates result in increased oxygen consumption and reduced diastolic filling times, thus compromising coronary perfusion. 20 Higher heart rates have also been associated with accelerated atherosclerosis and plaque rupture. 21 An elevated heart rate is associated with insufficient physical exercise 22 and is a marker of increased sympathetic nervous system activity, which may predispose to numerous morbid outcomes, including malignant arrhythmias and insulin resistance. 23 The beneficial effects of β-adrenoreceptor antagonists on mortality in HF have been well documented; however, the effect of heart rate lowering versus the nonchronotropic, pleiotropic effects of these agents have not been disentangled. 17 Although we found that a discharge heart rate >90 bpm was associated with higher mortality, despite β-adrenoreceptor antagonism, it could not be elucidated if pure heart rate lowering would add incremental benefits to optimal doses of β-adrenoreceptor antagonists. 20 Our study had several limitations. First, although there was a near-linear relationship between discharge heart rate and 1-year mortality, our findings did not establish causality. Interestingly, there have been mixed results using ivabradine, a selective I f current inhibitor that blocks the sinoatrial node thereby reducing heart rate without affecting other aspects of cardiac function. In the BEAUTIFUL (Morbidity-mortality evaluation of the I f inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction) trial, ivabradine did not reduce the primary end point of cardiovascular death, acute MI, and hospital admission for new onset or worsening HF. 24 Moreover, although heart rate lowering with ivabradine did reduce the primary composite end point of cardiovascular death or hospital admission for worsening HF in the SHIFT (Systolic Heart Failure treatment with the I f inhibitor ivabradine) trial, it did not reduce all-cause mortality. 11 Another limitation in our study was that LVEF was imputed for missing data in the EFFECT-HF cohort. Finally, although a single reading of discharge heart rate was examined with possible variability from unaccounted physiological factors such as excess sympathetic tone in the setting of cardiac stress, pharmacological influences including β-adrenoreceptor antagonist dose, and closely timed antecedent bronchodilator use, the resultant greater variation would likely have attenuated our results.
Conclusions
Higher discharge heart rate was associated with a greater risk of all-cause mortality, cardiovascular death, and hospitalizations for HF and cardiovascular causes among community-based patients who were discharged after an index HF hospitalization. Our study suggests that heart rate, an eminently modifiable prognostic marker, merits attention in the transition from hospital to ambulatory care in the community. Further studies are needed to define the beneficial effects of both pharmacological and nonpharmacological heart ratelowering interventions and to determine whether target ranges exist to guide therapy. 
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